A Most Singular Investment

by

A Most Singular Investment

It has come to our attention – a matter of some amusement, truth be told – that a fund, known as Crewe Advisors, has seen fit to acquire no less than 1,035,747 shares of a company called PACS Group. A prodigious sum, wouldn’t you agree? A transaction valued at approximately $22.72 million, to be precise. One might ask, why such enthusiasm for a purveyor of post-acute care? Is it a matter of genuine foresight, or merely a fashionable frenzy, a fleeting caprice of the market?

The Rising Star

This Crewe Advisors, in a gesture of considerable boldness – or perhaps desperation, time will reveal – has augmented its holdings in PACS Group, swelling its portfolio by the aforementioned number of shares. The total value of this position now stands at $82.45 million, a sum that would surely impress even the most extravagant of noblemen. One begins to suspect a certain… devotion. The fund’s quarter-end position reflects an increase of $67.19 million, a testament to both shrewd investment and, dare we say, a touch of good fortune.

A Portion of the Estate

Let us consider the proportions. This PACS Group now commands 7.3% of Crewe Advisors’ entire fortune. A significant stake, wouldn’t you concur? It suggests a belief – perhaps a misguided one – that this company holds the key to lasting prosperity.

The principal holdings of this fund, as of late, are as follows:

  • NYSEMKT:IVV: $137.22 million (12.2% of AUM)
  • NYSE:PACS: $82.45 million (7.3% of AUM)
  • NYSEMKT:SPY: $68.71 million (6.1% of AUM)
  • NYSEMKT:IJH: $61.43 million (5.4% of AUM)
  • NYSEMKT:IEFA: $49.30 million (4.4% of AUM)

Observe, if you will, that PACS Group holds its own amongst these broad market instruments. A curious alignment, wouldn’t you say?

A Company Profile

PACS Group, it appears, is in the business of tending to those in their twilight years. They offer facilities for post-acute care, assisted living, and the like. A noble pursuit, to be sure, though one wonders if profit is the sole motivation. They claim to generate revenue from healthcare services and related amenities. A rather transparent declaration, wouldn’t you agree?

Let us examine the figures:

Metric Value
Revenue (TTM) $5.14 billion
Net income (TTM) $169.04 million
Market capitalization $6.02 billion
Price (as of January 15) $39.37

The share price, as of late, stands at $39.37, an increase of 184.9% over the past year. A remarkable ascent, one might say. Though, one wonders if this rapid growth is sustainable, or merely a bubble waiting to burst.

The Meaning of This Folly

This acquisition, my friends, has elevated PACS Group to a position of prominence within Crewe Advisors’ portfolio. It sits alongside broad market ETFs, suggesting a belief that this company is not merely a fleeting fancy, but a solid, enduring investment. Though, one cannot help but wonder if this enthusiasm is justified. The timing is peculiar, to say the least. Shares have already climbed to dizzying heights, yet Crewe Advisors continues to pour capital into this venture. A bold move, or a reckless gamble?

Recent results offer a glimmer of explanation. The company reported third-quarter revenue of $1.34 billion, a 31% increase year over year. Occupancy rates at their facilities remain remarkably high, far exceeding industry averages. Perhaps, then, there is substance to this investment after all. Or perhaps, we are merely witnessing a masterful illusion, a carefully constructed façade of prosperity.

In essence, this is a wager on sustained cash generation and scale within a defensive growth industry. A sizable bet, to be sure, but one that is balanced by diversified index exposure elsewhere. A prudent approach, perhaps, or merely a desperate attempt to conceal a lack of imagination?

Read More

2026-01-18 13:03